Quest Diagnostics stock gains on Apple Health testing partnership

Published on 09/11/2026 at 11:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock closed at USD 235.50 on September 8, 2026, after a 0.69 percent daily drop. Apple Health testing was paired with trailing 12-month revenue of USD 11.56 billion.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics stock (ISIN US74834L1008) closed at USD 235.50 on September 8, 2026, after a 0.69 percent drop from USD 237.14 the day before. The Apple Health lab-testing partnership helped frame the move, while the companys trailing 12-month revenue stood at USD 11.56 billion.

Apple Health meets valuation

As ad hoc news reported on September 10, 2026, Quest Diagnostics stock traded at USD 235.50 on September 8, 2026, and the company was valued at about USD 25.5 billion. The same report put trailing 12-month diluted EPS at USD 9.42 and net income attributable to common shareholders at USD 1.06 billion.

That means the stock traded at 24.49 times trailing earnings, while the report also cited a profit margin of 9.19 percent. For investors, the ratio between USD 11.56 billion in revenue and USD 1.06 billion in net income remains the central valuation check.

Analysts lift estimates

According to MarketBeat on September 10, 2026, the Q3 2026 EPS estimate for Quest Diagnostics rose to USD 2.83 from USD 2.82, while the consensus rating stayed at Moderate Buy. The same update showed an average price target of USD 236.31.

On September 8, 2026, Yahoo Finance listed UBS as maintaining Neutral and raising its price target to USD 245 from USD 232. That target sits above the last close of USD 235.50 and keeps valuation debates active around the current quote.

Stock near the range

Quest Diagnostics stock last changed hands at USD 235.50 on September 8, 2026, with MarketBeat putting the 52-week range at USD 171.18 to USD 247.19 and market capitalization at USD 25.51 billion. The quote sits close to the upper end of that band and only a few dollars below the high.